published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRAPID (Sholzberg), 2021 0.22 [0.07; 0.67] 0.22[0.07; 0.67]RAPID (Sholzberg), 202110%465NAnot evaluable death or transfer to ICUdetailed resultsRAPID (Sholzberg), 2021 0.70 [0.44; 1.12] 0.70[0.44; 1.12]RAPID (Sholzberg), 202110%465NAnot evaluable deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20] COALIZAO ACTION, 2021 1.55 [0.90; 2.70] COVID-PACT, 2022 0.91 [0.56; 1.48] INSPIRATION, 2021 1.09 [0.78; 1.53] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38] 0.99[0.77; 1.26]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, INSPIRATION, 2021, RAPID (Sholzberg), 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021654%5,347moderatenot evaluable clinical deteriorationdetailed resultsCOALIZAO ACTION, 2021 1.35 [0.85; 2.15] RAPID (Sholzberg), 2021 0.69 [0.43; 1.10] Ravichandran, 2021 0.02 [0.00; 0.36] 0.67[0.25; 1.77]COALIZAO ACTION, 2021, RAPID (Sholzberg), 2021, Ravichandran, 2021382%1,290moderatenot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03] 0.83[0.67; 1.03]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,074NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57] 1.27[1.03; 1.57]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,219NAnot evaluable death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07] RAPID (Sholzberg), 2021 0.59 [0.34; 1.02] 0.76[0.58; 1.00]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, RAPID (Sholzberg), 2021211%2,696moderatenot evaluable mechanical ventilationdetailed resultsRAPID (Sholzberg), 2021 0.70 [0.32; 1.54] 0.70[0.32; 1.54]RAPID (Sholzberg), 202110%465NAnot evaluable viral clearance detailed resultsRavichandran, 2021 1.71 [0.80; 3.64] 1.71[0.80; 3.64]Ravichandran, 202110%122NAnot evaluable viral clearance by day 7detailed resultsRavichandran, 2021 1.71 [0.80; 3.64] 1.71[0.80; 3.64]Ravichandran, 202110%122NAnot evaluable ICU admissiondetailed resultsRAPID (Sholzberg), 2021 0.79 [0.48; 1.30] 0.79[0.48; 1.30]RAPID (Sholzberg), 202110%465NAnot evaluable Major thrombotic events or deathdetailed resultsCOVID-PACT, 2022 0.56 [0.32; 0.98] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36] 0.80[0.44; 1.46]COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021273%1,473moderatenot evaluable adverse eventsdetailed resultsRavichandran, 2021 1.04 [0.02; 52.86] 1.04[0.02; 52.86]Ravichandran, 202110%210NAnot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67] COALIZAO ACTION, 2021 2.50 [0.78; 8.06] COVID-PACT, 2022 3.86 [0.44; 34.07] INSPIRATION, 2021 1.83 [0.53; 6.34] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98] 1.80[1.18; 2.75]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202150%4,876moderateserious Thromboembolic eventsdetailed resultsCOALIZAO ACTION, 2021 0.73 [0.41; 1.29] INSPIRATION, 2021 1.07 [0.76; 1.49] 0.95[0.68; 1.34]COALIZAO ACTION, 2021, INSPIRATION, 2021221%1,176moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-06 06:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290